While the clinical evidence is clear in the head-to-head SURMOUNT-5 trial, published in 2024, that the weight loss with Tirzepatide is greater than with Semaglutide, that's not all that's relevant in your choice.
This long-awaited news is in. The United States Food & Drug Administration (FDA) has officially announced that it will be removing its black box warnings from most hormone replacement therapies (HRT) for menopause.
